Anand P Chokkalingam (A P Chokkalingam)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Hepatitis B Virus

End Stage Renal Disease

Top Venues

Alimentary pharmacology & therapeutics

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

This page only lists publications with an associated author ORCID identifier.

Publications

Dahlene Fusco, Ivana Malenica, Huldrych F Gunthard, Samir K Gupta, Dax Kurbegov, Bindu Balani, Susan Olender, Judith A Aberg, Laura E Telep, Yuan Tian, Christiana Blair, George Wu, Richard Haubrich, Chen-Yu Wang, Anand P Chokkalingam, Anu O Osinusi, Clemens-Martin Wendtner, Robert L Gottlieb
Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Mark S Sulkowski, Laura E Telep, Massimo Colombo, Francois Durand, K Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Lindsey Force, Heribert Ramroth, Anuj Gaggar, Anand P Chokkalingam, Meghan E Sise
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. Alimentary pharmacology & therapeutics 55 (9) (2022)
W Ray Kim, Laura E Telep, Belinda Jump, Mei Lu, Heribert Ramroth, John Flaherty, Anuj Gaggar, Anand P Chokkalingam, Stuart C Gordon
Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Alimentary pharmacology & therapeutics 55 (7) (2022)
W Ray Kim, Laura E Telep, Anand P Chokkalingam
Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-A "knock-out" is yet to be delivered-Authors' reply. Alimentary pharmacology & therapeutics 55 (10) (2022)
A W Singer, Rajender K Reddy, L E Telep, A O Osinusi, D M Brainard, M Buti, Anand P Chokkalingam
Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors' reply. Alimentary pharmacology & therapeutics 48 (2) (2019)
A W Singer, Rajender K Reddy, L E Telep, A O Osinusi, D M Brainard, M Buti, Anand P Chokkalingam
Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Alimentary pharmacology & therapeutics 47 (9) (2018)